Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Date:9/8/2009

ce Sheet Data (unaudited) June 30, 2009 June 30, 2008 ASSETS Current assets: Cash and cash equivalents $4,378,662 $9,421,770 Available-for-sale investments 3,439,650 3,352,771 Accounts receivable 508,528 5,747 Prepaid expenses and other current assets 492,824 484,362 Total current assets 8,819,664 13,264,650 Property and equipment, net 3,650,783 5,128,076 Restricted cash 475,000 475,000 Other assets 254,364 257,198 Total assets $13,199,811 $19,124,924 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Capital lease obligations, current portion $87,675 $263,128 Accounts payable 206,363 635,183 Accrued expenses 1,420,741 1,666,628 Accrued compensation - 767,509 Deferred revenue, current portion 2,650,002 1,666,669 Total current liabilities 4,364,781 4,999,117 Capital lease obligations, net of current portion 33,954 121,629 Deferred rent, net of current portion 1,182,026 1,479,794 Deferred revenue, net of current portion 4,305,551 5,972,220 Total liabilities 9,886,312 12,572,760 Stockholders' equity: Preferred stock of $0.01 par value - authorized 10,000,000 shares; Series A Convertible; issued and outstanding 4,997 shares as of
'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Francisco, California (PRWEB) July 31, 2014 ... systems that inform therapeutic decision-making in oncology, today announced ... August 14, 2014 to discuss the Company's financial results ... provide an update about the business in the current ... audio call beginning on Thursday, August 14, 2014, at ...
(Date:7/31/2014)... 31, 2014 Rancho BioSciences , ... of Omicsoft’s Array Suite with tranSMART . ... able to send data in tranSMART to Array Suite ... versions of tranSMART including the new 1.2 release. ... and storage for the analysis of high dimensional quantification ...
(Date:7/31/2014)... MA (PRWEB) July 31, 2014 ... (UC) and collaboration company, is proud to announce ... (LMS). LMS complements Adobe Connect’s elearning tools to ... LMS delivers content with training tools for desktop ... eLearning with LMS is the perfect online training ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... , SOUTH PLAINFIELD, N.J., Sept. 2 PTC ... its option to collaborate on advancing drug discovery efforts on ... (Gene Expression Modulation by Small-molecules) technology. , , ... , , In September 2007, Celgene made ...
... , SAN DIEGO, Sept. 2 Results from ... developmental product candidates will be presented at the ... held at The Moscone Center in San Francisco on September 12-15, 2009. ... , , , Fidaxomicin ...
... , SOUTH SAN FRANCISCO, Calif., Sept. ... the first commercial sales of a new 20 microgram per ... York Heart Association Class III and IV pulmonary arterial hypertension ... Ventavis in half the volume, which is expected to reduce ...
Cached Biology Technology:PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 2Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 3
(Date:7/30/2014)... researchers from the University of Helsinki and the Universitat ... in mice morphological changes which have taken millions of ... the embryonic development of mice teeth, induced in the ... similar to those observed in the fossil registry of ... ago. , To modify the development of their ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
(Date:7/30/2014)... Limited today announced an across-the-board increase in Impact ... 2013 InCites Journal Citation Reports (Thomson Reuters, 2014) ... Journal , Essays in Biochemistry , ... all received increases in their Impact Factors. ... and published by Portland Press Limited. , 2014 ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2
... Studying thousands of patients, Japanese researchers have found a ... three cancers esophageal, head and neck, and lung. ... of developing these diseases. In the May issue ... the American Association for Cancer Research, scientists from Aichi ...
... A Swiss marine biologist and an Australian quantum physicist have ... Reef, Australia, can see a world invisible to all other ... have shown that mantis shrimp not only have the ability ... but have optimal polarisation vision a first for any ...
... in the February 2008 issue of HortScience offers new ... athletic fields ready for fall sports more quickly. Results ... pare down the usual 9- to 12-month waiting period ... autumn football traffic. Dr. John Stier, Associate Professor ...
Cached Biology News:Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2Shrimps see beyond the rainbow 2Shrimps see beyond the rainbow 3Establishing faster-growing, durable football fields 2
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
Biology Products: